Peppermint oil has been reported to help relieve symptoms of IBS in two analyses of controlled trials. In the intestinal tract, oil reduces gas production, eases intestinal cramping, and soothes irritation. For a supplement, little scientific support.
We hope this provides you with a helpful resource to make informed decisions towards your health and well-being.ģ Stars Reliable and relatively consistent scientific data showing a substantial health benefit.Ģ Stars Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal health benefit.ġ Star For an herb, supported by traditional use but minimal or no scientific evidence. To help you make educated decisions, and to better understand controversial or confusing supplements, our medical experts have digested the science into these three easy-to-follow ratings. While there is no way to predict whether a vitamin, mineral, or herb will successfully treat or prevent associated health conditions, our unique ratings tell you how well these supplements are understood by the medical community, and whether studies have found them to be effective for other people.įor over a decade, our team has combed through thousands of research articles published in reputable journals. Future studies should assess the long-term efficacy and safety of peppermint oil and its efficacy relative to other IBS treatments including antidepressants and antispasmodic drugs.Our proprietary “Star-Rating” system was developed to help you easily understand the amount of scientific support behind each supplement in relation to a specific health condition. Peppermint oil is a safe and effective short-term treatment for IBS. The most commonly reported adverse event was heartburn. Although peppermint oil patients were significantly more likely to experience an adverse event, such events were mild and transient in nature. Peppermint oil was found to be significantly superior to placebo for global improvement of IBS symptoms (5 studies, 392 patients, relative risk 2.23 95% confidence interval, 1.78-2.81) and improvement in abdominal pain (5 studies, 357 patients, relative risk 2.14 95% confidence interval, 1.64-2.79). The risk of bias was low for most of the factors assessed. Nine studies that evaluated 726 patients were identified. Outcomes were analyzed using an intention-to-treat approach.
Outcomes included global improvement of IBS symptoms, improvement in abdominal pain, and adverse events.
Study quality was evaluated using the Cochrane risk of bias tool. A literature search upto February 2013 identified all applicable randomized-controlled trials. Cross-over studies that provided outcome data before the first cross-over were included. Randomized placebo-controlled trials with a minimum treatment duration of 2 weeks were considered for inclusion. Medical interventions are limited and the focus is on symptom control. IBS is a common disorder that is often encountered in clinical practice. The aim of this study was to assess the efficacy and safety of enteric-coated peppermint oil capsules compared with placebo for the treatment of active irritable bowel syndrome (IBS).
0 kommentar(er)
